🇺🇸 FDA
Pipeline program

BNT327, BNT323

BNT323-03

Phase 2 small_molecule active

Quick answer

BNT327, BNT323 for Advanced Breast Cancer Metastatic Breast Cancer is a Phase 2 program (small_molecule) at BioNTech Manufacturing GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
BioNTech Manufacturing GmbH
Indication
Advanced Breast Cancer Metastatic Breast Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials